Business Description
ALX Oncology Holdings Inc. is a US-based clinical-stage company working to develop new cancer treatments. Its main drug candidate, Evorpacept, works by blocking a protein called CD47 and is being tested in combination with other cancer therapies across multiple clinical trials targeting conditions such as gastric cancer, breast cancer, multiple myeloma, and lymphoma. The company has built partnerships with organizations including Jazz Pharmaceuticals, MD Anderson Cancer Center, and Sanofi to advance these programs. Founded in 2015 and based in South San Francisco, California, ALX Oncology also holds a licensing agreement with Stanford University.
